Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Prior treatment

• Subjects who have received a bendamustine containing regimen and relapsed less than one year after the end of treatment.
• Allogenic stem cell transplant within 6 months prior to start of first study drug.
• Previous treatment with CD19 targeting agents.
• More than four lines of previous treatment (autologous stem cell transplant performed as part of consolidation to a previous line of therapy should not be considered as a line of therapy).
• Major surgery or any anticancer therapy including chemotherapy, immunotherapy, radiotherapy, investigational therapy, including targeted small molecule agents within 14 days prior to start of study drug (R-BAC). A shorter interval in special settings must be approved by the Sponsor and/or Investigator.
• Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
  • Uncontrolled and/or active systemic infection (viral including COVID 19, bacterial or fungal);
  • Chronic or acute hepatitis B (HBV) or hepatitis C (HCV) requiring treatment. Note:
  • subjects with serologic evidence of prior vaccination to HBV (i.e., HBsAg negative, HBsAb positive and HBcAb negative) or positive HBcAb from previous infection or intravenous immunoglobulins (IVIG) may participate; inactive carriers (HBsAg positive with undetectable HBV DNA) are eligible. Patients with presence of HCV antibody are eligible only if PCR results (polimerase chain reaction) negative for HCV RNA.

Other illness

• Known history of hypersensitivity to human antibodies.
• Allogenic stem cell transplant with active / uncontrolled graft-versus-host disease.
• Active second malignancy in the last three years other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or any other tumor that the Sponsor and Coordinating Investigator agree and document should not be considered preclusive to participate in the study.
• Cardiovascular disease (NYHA, New York Heart Association, class ≥2).
• Significant history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent.
• HIV seropositivity.
• Lymphoma with active CNS (central nervous system) involvement at the time of screening, including leptomeningeal disease.
• Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgment, make the patient inappropriate for study participation or put the patient at risk.

Lab values

• Congenital long QT syndrome or a corrected QTcF interval of \>480 msec at screening (unless secondary to pacemaker or bundle branch block).

Other

• If female, the patient is pregnant or breast-feeding.

• Histologically documented diagnosis of MCL as defined in the 2017 edition of the World Health Organization (WHO) classification
• Age ≥ 18 and \< 85 years
• Relapsed/Refractory disease after one, two, three or four lines of treatment
• Bendamustine-naive or relapsed after at least one year after the last cycle of a bendamustine-containing regimen
• Previous treatment with BTKi (Bruton Tyrosine Kinase inhibitors) monotherapy or BTKi containing regimens with R/R disease; and/or patients who discontinued BTKi monotherapy or BTKi containing regimens for adverse events and have active disease necessitating treatment.
• Previous treatment with any anti-CD19 agents is allowed (included CAR-T treatment) If previous anti-CD19 treatment has occurred, tissue CD19 expression must be assessed by histology or flow cytometry
• Venetoclax treated patients are allowed.
• Stem cell transplant eligible patients are allowed.
• Measurable nodal or extranodal disease ≥ 1.5 cm in longest diameter, and measurable in 2 perpendicular dimensions. Note: Patients with bone marrow involvement only are eligible. In case of bone marrow infiltration only, bone marrow aspiration and biopsy are mandatory for all staging evaluations
• ECOG (Eastern Cooperative Oncology Group)/WHO (World Health Organization) performance status ≤ 2 (unless MCL-related)
• The following laboratory values at screening (unless due to bone marrow involvement by lymphoma):
  • Absolute Neutrophil count (ANC) \> 1.0×109/L
  • Platelet count ≥ 75.000/mm3
  • Creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula)
  • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN (upper limit of normal)
  • Bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non- hepatic origin)
• Subject understands and voluntarily signs an informed consent form approved by an Independent Ethics Committee (IEC), prior to the initiation of any screening or study-specific procedures.
• Subject must be able to adhere to the study visit schedule and other protocol requirements.
• Life expectancy ≥ 3 months.
• Women of childbearing potential (WOCBP) and men must agree to use effective contraception if sexually active.This applies for the time period between signing of the informed consent form and at least 10 months after last loncastuximab tesirine (ADCT-402) dose. Men with female partners who are of childbearing potential must agree to use effective contraception if sexually active. This applies for the time period between signing of the informed consent form and at least 7 months after last loncastuximab tesirine (ADCT-402) dose.